Paras Biopharmaceuticals Finland OY, a biopharma technology development company based in Oulu, Finland, has announced its inclusion as "one of the top pharma outsourcing companies in Europe for the year 2021". The name was selected by PharmaTech Outlook, USA, an online magazine pioneering as a one-stop- hub for product trends, solutions that evaluates and selects key players from well-established companies. The recognition highlights Paras Biopharma's successful concept of developing flawless biologics for rare and orphan diseases in large-scale production. This is achieved by using the company's robust manufacturing processes and unique technologies, ensuring its clients' requirements are met beyond expectation by decoding difficult biologic medicines for unmet medical needs.
"Paras Biopharma primary objective is to address the intrinsic challenges of biologics manufacturing by incorporating its unique technologies in creating pioneering solutions in order to make healthcare more affordable," said the company in a press statement. "Paras Biopharma brings together a unique mix of top-class academic or industrial experience and its microbial biologics development technologies to achieve the requirements of customer needs for the development and production of recombinant biologics," added the note. “Extreme levels of inefficiencies in the manufacturing of biologics are responsible for increased costs and ineffective results in treating unmet clinical needs of patients,” said Dr Ashesh Kumar, CEO, Paras Biopharma. “Paras Biopharma welcomes the opportunity to expand on its innovations that strive to reach the targets of those unmet medical needs,” added Dr Mark Jackson, Administration Lead, Paras Biopharma.
